The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for a combination of the potential therapy NKTR-214 with Opdivo (nivolumab) for untreated melanoma patients with either metastatic disease or who are unable to undergo surgery.
Archive | Regulatory
NKTR-214 with Opdivo Earns FDA’s Breakthrough Therapy Designation for Advanced Melanoma
Posted in Melanoma News, Regulatory, Publications
Bempegaldesleukin Plus Nivolumab Granted Breakthrough Designation in Melanoma by the FDA
The combination of bempegaldesleukin (NKTR-214) and nivolumab (Opdivo) was granted a breakthrough therapy designation by the FDA for the treatment of patients with previously untreated unresectable or metastatic melanoma.
Posted in Melanoma News, Regulatory, Publications
FDA Approval in TGCT, Breakthrough Designation in Melanoma, and More
An FDA approval in tenosynovial giant cell tumor, a breakthrough therapy designation in melanoma, and encouraging findings in trials in bladder cancer, lung cancer, and a cell-free DNA assay.
Posted in Melanoma News, Regulatory, Publications
FDA Will Review Application Seeking Expansion of Keytruda’s Dosing Schedule
The U.S. Food and Drug Administration (FDA) has accepted for review six supplemental biologics license applications (sBLAs) seeking to expand the dosing schedule of Keytruda (pembrolizumab) so the medication can be administered every six weeks.
Posted in Melanoma News, Patients, Regulatory, Latest News, Publications
